Steven Gillis

Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a Founder and Director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its Chairman, until its acquisition by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was Founder and Director of Immunex Corporation, which was acquired by Amgen for $16B. During his tenure, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. He was interim Chief Executive Officer of Immunex following its majority purchase by American Cyanamid Company, and was also a Board Member. He is credited as a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, Prokine and Enbrel, and the regulatory approval of Bexxar and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College and his Ph.D. from Dartmouth College. He is an immunologist by training with over 300 peer-reviewed publications, and serves as a Director or Chairman in multiple private and publicly-held biotechnology companies.